OptiNose

Woman blowing nose

Biotech

Lyra bags $29.5M to push chronic sinusitis drug into phase 2

Lyra Therapeutics' series B will move its lead program, a rhinosinusitis treatment based on its transmucosal drug delivery platform, into phase 2.

Amirah Al Idrus Sep 26, 2018 8:17am

ladders3

Chutes & Ladders—Grail loses a trio of top executives

Nov 3, 2017 9:15am

Nasdaq

Fresh from FDA approval, Optinose files for $100M IPO

Sep 20, 2017 4:53am